EW Edwards Lifesciences Corporation

Price (delayed)

$76.58

Market cap

$48.13B

P/E Ratio

65.05

Dividend/share

N/A

EPS

$1.19

Enterprise value

$47.91B

Sector: Healthcare
Industry: Medical Devices
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Highlights

The equity has grown by 10% year-on-year
The company's EPS fell by 33% QoQ but it rose by 2.6% YoY
The net income has contracted by 33% from the previous quarter but it has grown by 2.6% YoY
The price to earnings (P/E) is 51% higher than the 5-year quarterly average of 43.1 and 31% higher than the last 4 quarters average of 49.7
EW's quick ratio is down by 11% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of EW
Market
Shares outstanding
621.74M
Market cap
$48.13B
Enterprise value
$47.91B
Valuations
Price to earnings (P/E)
65.05
Price to book (P/B)
12.49
Price to sales (P/S)
11.11
EV/EBIT
57.13
EV/EBITDA
49.83
EV/Sales
11.09
Earnings
Revenue
$4.32B
EBIT
$838.6M
EBITDA
$961.4M
Free cash flow
$936.8M
Per share
EPS
$1.19
Free cash flow per share
$1.51
Book value per share
$6.2
Revenue per share
$6.97
TBVPS
$7.94
Balance sheet
Total assets
$6.42B
Total liabilities
$2.59B
Debt
$684.5M
Equity
$3.84B
Working capital
$1.82B
Liquidity
Debt to equity
0.18
Current ratio
3.08
Quick ratio
1.98
Net debt/EBITDA
-0.23
Margins
EBITDA margin
22.2%
Gross margin
75%
Net margin
17.2%
Operating margin
18.3%
Efficiency
Return on assets
11.9%
Return on equity
18.9%
Return on invested capital
23.3%
Return on capital employed
15.1%
Return on sales
19.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EW stock price

How has the Edwards Lifesciences stock price performed over time

Financial performance

How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$4.32B
Gross profit
$3.24B
Operating income
$790.1M
Net income
$743.6M
Gross margin
75%
Net margin
17.2%
The operating income has contracted by 35% from the previous quarter
The net income has contracted by 33% from the previous quarter but it has grown by 2.6% YoY
The company's operating margin fell by 33% QoQ and by 8% YoY
The net margin has contracted by 30% from the previous quarter and by 6% YoY

Valuation

What is Edwards Lifesciences stock price valuation
P/E
65.05
P/B
12.49
P/S
11.11
EV/EBIT
57.13
EV/EBITDA
49.83
EV/Sales
11.09
The price to earnings (P/E) is 51% higher than the 5-year quarterly average of 43.1 and 31% higher than the last 4 quarters average of 49.7
The company's EPS fell by 33% QoQ but it rose by 2.6% YoY
The stock's price to book (P/B) is 34% more than its 5-year quarterly average of 9.3 and 12% more than its last 4 quarters average of 11.2
The equity has grown by 10% year-on-year
The P/S is 32% above the 5-year quarterly average of 8.4 and 9% above the last 4 quarters average of 10.2
EW's revenue is up by 9% year-on-year but it is down by 3.6% since the previous quarter

Efficiency

How efficient is Edwards Lifesciences business performance
The company's return on invested capital fell by 37% QoQ and by 12% YoY
EW's return on assets is down by 35% since the previous quarter and by 9% year-on-year
Edwards Lifesciences's return on equity has decreased by 34% QoQ and by 13% YoY
The company's return on sales fell by 32% QoQ and by 7% YoY

Dividends

What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EW.

Financial health

How did Edwards Lifesciences financials performed over time
The total assets is 149% greater than the total liabilities
The company's total liabilities rose by 25% YoY and by 19% QoQ
The total assets is up by 15% year-on-year and by 6% since the previous quarter
The debt is 82% less than the equity
The company's debt to equity rose by 6% QoQ but it fell by 5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.